Myocardial infarction secondary to 5-fluorouracil: not an absolute contraindication to rechallenge?
Department of Cardiology, The Prince Charles Hospital, Chermside, Queensland, Australia.
Shruti
S
Rateesh
Department of Cardiology, The Prince Charles Hospital, Chermside, Queensland, Australia; Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, Rochester, MN, United States; School of Medicine, University of Queensland, Herston, Queensland, Australia. Electronic address: Luis.Sushil@mayo.edu.
Sushil A
SA
Luis
Department of Cardiology, The Prince Charles Hospital, Chermside, Queensland, Australia.
Chris R
CR
Luis
Department of Oncology, The Prince Charles Hospital, Chermside, Queensland, Australia.
Brett
B
Hughes
Department of Cardiology, The Prince Charles Hospital, Chermside, Queensland, Australia.
Mugur
M
Nicolae
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D004334:Drug Administration Schedule; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000139:chemically induced* / Q000000981:diagnostic imaging*; D011859:Radiography
D000970:Antineoplastic Agents; D005472:Fluorouracil
5-Fluorouracil; Cancer; Chemotherapy; Colon cancer; Coronary vasospasm; Myocardial infarction